CHMP Recommends Approval of New Indication for Enbrel as Treatment for Severe Psoriasis in Paediatric Patients
The European Committee for Medicinal Products for Human Use (CHMP) announced its positive recommendation for the approval of Enbrel (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the European Commission, following the Committee's recommendation, Enbrel will become the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently approved in the European Union for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, psoriatic arthritis, moderate to severe rheumatoid arthritis (RA) in adults, and polyarticular juvenile idiopathic arthritis (JIA) in children. [more...]
|
|
|
